stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) EPS (diluted)
Xeris Biopharma Holdings, Inc.'s EPS (diluted) for fiscal 2025 was $0.00, compared with −$0.37 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.05. Over the past ten years it has ranged from −$13.09 (fiscal 2017) to $0.00 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 8 consecutive fiscal years. Xeris Biopharma Holdings, Inc. ranks 28th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.00 | — |
| FY2024 | −$0.37 | — |
| FY2023 | −$0.45 | — |
| FY2022 | −$0.70 | — |
| FY2021 | −$1.55 | — |
| FY2020 | −$2.14 | — |
| FY2019 | −$4.81 | — |
| FY2018 | −$4.99 | — |
| FY2017 | −$13.09 | — |
| FY2016 | −$7.17 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.06 | — |
| Jun 2026 | −$0.18 | — |
| Mar 2026 | $0.01 | (83.33%) |
| Dec 2025 | $0.06 | 1,614.29% |
| 33 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | $3.24 |
| XERS Xeris Biopharma Holdings, Inc. | −$0.05 |
| ALVO Alvotech compare | −$1.24 |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$1.42 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$1.43 |
| TRLV Trulieve Cannabis Corp. compare | −$2.47 |
| PRGO Perrigo Company plc compare | −$12.76 |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on XERS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement